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Background: Cyclotides are useful scaffolds to stabilize bioactive peptides.
Results: Four melanocortin analogues of kalata B1 were synthesized. One is a selective MC4R agonist.
Conclusion: The analogues retain the native kalata B1 scaffold and introduce a designed pharmacological activity, validating
cyclotides as protein engineering scaffolds.
Significance: A novel type of melanocortin agonist has been developed, with potential as a drug lead for treating obesity.
Obesity is an increasingly important global health problem
that lacks current treatment options. The melanocortin recep-
tor 4 (MC4R) is a target for obesity therapies because its activa-
tion triggers appetite suppression and increases energy expend-
iture. Cyclotides have been suggested as scaffolds for the
insertion and stabilization of pharmaceutically active peptides.
In this study, we explored the development of appetite-reducing
peptides by synthesizing MC4R agonists based on the insertion
of the His-Phe-Arg-Trp sequence into the cyclotide kalata B1.
The ability of the analogues to fold similarly to kalata B1 but
display MC4R activity were investigated. Four peptides were
synthesized using t-butoxycarbonyl peptide chemistry with a
C-terminal thioester to facilitate backbone cyclization. The
structures of the peptides were found to be similar to kalata B1,
evaluated by H NMR chemical shifts. KB1(GHFRWG;23–28)
had a Ki of 29 nM at the MC4R and was 107 or 314 times more
selective over this receptor than MC1R or MC5R, respectively,
andhadnodetectable binding toMC3R.The peptide hadhigher
affinity for the MC4R than the endogenous agonist, -melano-
cyte stimulation hormone, but it was less potent at the MC4R,
with an EC50 of 580 nM for activation of the MC4R. In conclu-
sion, we synthesized melanocortin analogues of kalata B1 that
preserve the structural scaffold and display receptor binding
and functional activity. KB1(GHFRWG;23–28) is potent and
selective for theMC4R. This compound validates the use of cyc-
lotides as scaffolds and has the potential to be a new lead for the
treatment of obesity.
Obesity is an increasing problem world wide with 1.5 billion
adults estimated to be overweight (body mass index above 25
kg/m2) and500millionobese (bodymass indexabove30kg/m2) in
2008 (1). These statistics are alarming given that obesity is associ-
ated with a risk of developing a variety of debilitating diseases,
including type 2 diabetes, cardiovascular disease, and hyperten-
sion (2–4). To prevent or reduce obesity and the risk of related
diseases, regular exercise and a healthy diet are very effective (5),
but in high risk patients drug treatment is also necessary (6). Cur-
rently, only twodrugsareapproved for the treatmentofobesity, i.e.
orlistat and phentermine. The Food and Drug Administration
withdrew sibutramine in 2010 because of increased risk of cardio-
vascular events (7). Although drugs currently on the market for
other indicationsareundergoingclinical trials for theirpotential to
treat obesity, there is still an urgent need for new drugs targeting
the world-wide obesity problem.
One approach to the development of drugs for the treatment
of obesity is to target the melanocortin system, which includes
a family of five G-protein-coupled receptors, the melanocortin
receptors (MCR),3 namedMCR1–5 in the order of their discov-
ery (8–12). The endogenous peptide agonists, adrenocortico-
tropic hormone and -, -, and -melanocyte-stimulating
hormone (MSH), all derived from the precursor protein pro-
opiomelanocortin, form part of the system, in addition to the
inverse agonists agouti protein and agouti-related protein.
The five MCRs are distributed throughout the body and are
associated with a variety of physiological effects. MC1R is
mainly present in melanocytes and melanoma cells (8, 9).
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MC2R is present in the adrenal cortex, where it regulates ste-
roidogenesis, and is only activated by adrenocorticotropic hor-
mone, in contrast to the other MCRs (8). MC3R is mainly
expressed in the arcuate nucleus (13) but is also present in the
gut (10). MC4R is found throughout the brain (14) and in the
spinal cord and dorsal root ganglions (15). Stimulation of
MC4R reduces food intake and increases the metabolic rate in
mice (16), whichmakes it an interesting target for the treatment
of obesity. MC5R is distributed throughout the body with high
levels found in skeletal muscle, brain, and exocrine glands and
has a variety of functions (12, 17, 18).
The MSH peptides and adrenocorticotropic hormone share
the tetrapeptide His-Phe-Arg-Trp pharmacophore, which
is the shortest peptide active on the MCRs (19). Various mod-
ifications to these peptides have been made to explore the role
of individual amino acids. Substitution ofMet4 with norleucine
(Nle) and modifying the conformation of Phe7 to D-Phe in
-MSH (see Table 1) yielded a stable subnanomolar agonist
named NDP--MSH (20). Additionally, it has been shown that
the His-D-Phe-Arg-Trp tetrapeptide alone has nanomolar
activity on theMC4R (21). Inanother study, a truncatedanalogue
of the inverse agonist agouti-related protein was turned into a full
agonist by exchanging the binding sequence withHis-D-Phe-Arg-
Trp (22). These findings suggest that it might be possible to graft
the His-Phe-Arg-Trp sequence and related modified sequences
into stable peptide frameworks to develop novel MCR agonists.
The motivation for the grafting is to place the bioactive tetrapep-
tide in a molecular context where is will be less susceptible to
proteolysis andwill havemore favorable biopharmaceutical prop-
erties than the isolated peptide sequence.
The concept of developingMC4R agonists for the treatment
of obesity has been around formore than a decade, and agonists
have been shown to have efficacy in rodent models of obesity
(23). However, despite strenuous efforts, no compounds have
reached clinical trials for the treatment of obesity. The similar-
ity between the various MCRs, which makes it challenging to
make selective agonists, and the generally low half-lives of pep-
tides in vivo (24) have probably contributed to this lack of
success.
Recent discoveries of naturally occurring stable peptides
offer the potential to overcome some of the limitations of pep-
tides as drug leads. In the mid-1990s, several ultra-stable pep-
tides that had both a cyclic backbone and three disulfide bonds
forming a cystine knot were discovered (25–28). The most
extensively studied of these is the 29-residue peptide kalata B1
found in the African plantOldenlandia affinis (26), which orig-
inally attracted attention because of its reported uterotonic
activity (29). More recently, it has been reported to have anti-
microbial (30) and cancer cell cytotoxic activity (31) as well as a
range of other activities (32). Its biological function in the plant
is thought to be as a host defense pesticidal agent, because it
reduces the growth of the larvae of the crop pest Helicoverpa
punctigera (33). Following additional discovery efforts (34–38)
since these early studies, the group of cyclic cystine-knotted
(CCK) peptides now includes several hundred sequences and
has been given the name cyclotides (35, 39). They are excep-
tionally stable toward enzymatic or thermal degradation
because of their cyclic backbone and cystine knot (26, 28, 40).
Because of their stability and large sequence variation in nature,
cyclotides have been suggested as promising scaffolds for the
grafting of pharmaceutically interesting peptides to stabilize
them (35, 41). There are six backbone loops decorating the cys-
tine knot core, and these offer opportunities for conformational
control of a variety of peptide epitopes. In addition to being
amenable to solid phase peptide synthesis (30, 42), cyclotide
libraries have recently been expressed in bacterial cells (43),
thus providing alternative routes to their manufacture.
There are currently only a few examples demonstrating the
grafting of biologically active sequences into cyclotides or
related acyclic cystine knot scaffolds. For example, Clark et al.
(44) demonstrated that it was possible to substitute selected
amino acids in loop 5 of kalata B1 to remove intrinsic hemolytic
activity but retain the native fold, and later studies on this
framework demonstrated efficacy for grafted antiangiogenic
sequences (45) and bradykinin antagonists (46). Thongyoo et
al. (47) changed the specificity of the trypsin inhibitor cyclotide,
MCoTI-II, toward other proteases with one to three amino acid
substitutions, and Chan et al. (48) reported a novel angiogenic
agent based on this framework. In acyclic cystine-knotted pep-
tides, Reiss et al. (49) successfully grafted platelet aggregation
inhibiting sequences, and as mentioned above, agouti-related
protein was turned into a full agonist on the melanocortin
receptors (22).
In this study, kalata B1 was used as a scaffold for the insertion
(grafting) of melanocortin receptor-activating sequences. The
grafted sequences are shown inFig. 1 alongwith theNMR-derived
structure of kalata B1. These analogues have the potential to
become leads for a newclass ofmelanocortin receptor agonists for
the treatment of obesity. More broadly, they will expand knowl-
edge on the applicability of cyclotides as scaffolds.
EXPERIMENTAL PROCEDURES
Peptide Synthesis—Peptides were synthesized manually by Boc
solid phase peptide synthesis on a Boc-Gly-phenylacetamido-
methyl resin using 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-
uronium hexafluorophosphate or 2-(6-chloro-1-H-benzotri-
azol-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
as coupling reagents, as described previously (44). Mercapto-
propionic acid was used as a linker to facilitate backbone cycli-
zation by native chemical ligation (50). Peptides were cleaved
from the resin using hydrogen fluoride/cresol/thiocresol (50:
4:1 v/v/v), precipitated in diethyl ether, and lyophilized. The
crude peptides were purified using HPLC with a gradient of
25–45% solvent B (90% acetonitrile, 0.1%TFA inwater) against
solvent A (0.1% TFA in water) over 40min. A Phenomenex C18
column was used and absorbance measured at 280 nm. Back-
bone cyclization and disulfide bonds were formed using 0.1 M
ammonium bicarbonate (pH 8.2), isopropyl alcohol (50:50, v/v)
buffer for 48 h, at a peptide concentration of 0.2 mg/ml. At 0
and 24 h, 1 mM reduced glutathione was added. The oxidized
peptideswere purified onHPLCwith 30–50% solvent B over 60
min. The peptides were characterized using electrospray ioni-
zation mass spectrometry; the purity was determined by RP-
ultra-performance liquid chromatography, and the peptides
were quantified using a chemiluminescent nitrogen detector
(51).
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NMR—Peptides were dissolved at a concentration of1 mM
in 10% D2O and 90%H2O. Spectra were recorded at 298 K on a
Bruker AVANCE 600 MHz NMR spectrometer. Two-dimen-
sional spectra recorded included TOCSY, NOESY, and DQF-
COSY. The mixing times for the TOCSY and NOESY spectra
were 80 and 200 ms, respectively. The processed spectra were
analyzed using the program CcpNMR Analysis, University of
Cambridge, UK. Three-dimensional structures were calculated
from the recorded two-dimensional spectra using CYANA as
described previously (52). Structures were analyzed usingMol-
probity and PROMOTIF (53) and displayed usingMolMol (54)
and PyMol (55). Structures and chemical shifts have been
deposited in the Protein Data Bank (Protein Data Bank code
2lur) and Biomagnetic Resonance Bank (BMRB ID 18536),
respectively.
Melanocortin Assays—Melanocortin receptor binding assays
were conducted as described previously (56). Each assay was
performed in duplicate, and three assays were done on each
receptor. Peptides (3 pM to 3 M) were incubated with homog-
enized membranes from baby hamster kidney cells expressing
the various MCRs and 125I-NDP--MSH (around 60,000
counts/min). The incubation was stopped after 1 h by filtration
through polyethyleneimine-treated filter plates. Scintillation
liquid was added to the plates, and the radioactivity was
counted.
The cAMP activity assays were conducted on baby hamster
kidney cells expressing theMC4R, using the FlashPlateTM assay
as described previously (56). Cells and peptide (100 fM to 10M
to) were incubated and shaken for 30min at room temperature.
Detectionmixture was added according to FlashPlate protocol,
shaken for 30 min, and incubated overnight. The amount of
cAMPproducedwasmeasured by displacement of radiolabeled
cAMP bound to anti-cAMP antibodies in accordance with the
FlashPlate protocol.
The data analyses from the receptor assays were performed
as described previously (56), using the program GraphPad
Prism, GraphPad Software. IC50 values were calculated using a
nonlinear regressionmodel, andKi values were calculated from
the IC50 values. The potency at the MC4R was determined as
EC50 values, calculated by nonlinear regression of the activity
assay data.
Enzymatic Cleavage Assays—Peptides were incubated with
chymotrypsin (1:5 w/w enzyme/peptide ratio) at 37 °C. For
-MSH, the ratiowas 1:10w/w enzyme/peptide to have close to
equal molar ratios for all peptides. Samples were aliquoted out
and quenched with TFA before analysis on ultra-performance
liquid chromatography. Peak heights were used to calculate the
amount of intact peptide.
RESULTS
Design, Synthesis, and Characterization of the Grafted
Peptides—Four melanocortin analogues of kalata B1 were syn-
thesized using solid phase Boc chemistry. The sequences of the
peptides are shown in Table 1. They are named to reflect the
grafted epitopes incorporated into the kalata B1 (kB1)
sequence. For example, kB1(HFRW;24–27) indicates replace-
ment of residues 24–27 in loop 6 of kalata B1 (kB1) with the
HFRW (His-Phe-Arg-Trp) tetrapeptide sequence. In this case,
the tetrapeptide is flanked by the remaining native amino acids
in loop 6, i.e. T at the N-terminal side and PV at the C-terminal
side, making the total composition of loop 6 THFRWPV in
place of the native TRNGLPV. To account for the possibility
that direct replacements might constrain the bioactive tetra-
peptide in a nonactive conformation, other grafts were made
where flanking glycine residues were used in place of the native
kalata B1 residues.
The peptides were assembled attached to a C-terminal mer-
captopropionic acid linker to facilitate subsequent cyclization
of the termini. The linear precursor peptides were synthesized
with Val21 as the C terminus, because this allowed the synthesis
of one batch of resin to which was coupled the first 22 amino
acids common to all analogues. This batch was subsequently
split to continue separate synthesis of the differing parts of the
four analogues. Loop 6 was chosen as the site for grafting the
melanocortin sequence, because it is the largest of the inter-
cysteine loops in kalata B1. In addition, the structure of kalata
B1 shown in Fig. 1 indicates that the other loops are not in close
proximity with loop 6 and therefore are not likely to interfere
with the presentation of the grafted melanocortin sequence to
the MCRs.
The peptides were cleaved from the resin and then oxidized
and cyclized in a single step at 0.2 mg/ml concentration in a 0.1
M ammonium bicarbonate (pH 8.2), isopropyl alcohol (50:50,
v/v) buffer for 48 h with 1 mM reduced glutathione added at 0
FIGURE 1. a, primary sequence of kalata B1. The disulfide bonds and circular
backbone are indicated with lines, and the inter-cysteine loops are labeled
below the sequence. Loop 6, in which the melanocortin sequences are
grafted, is highlighted in blue. b, four sequences grafted into loop 6. The
lowercase f refers to D-Phe. Non-native kalata B1 residues are highlighted in
red. c, structure of kalata B1 (Protein Data Bank code 1nb1), with disulfides
indicated, and loop 6 highlighted in blue (62).
TABLE 1
Nomenclature, sequences, and disulfide pattern of grafted cyclotides
with their correspondingmasses
The sequence of -MSH is shown below.
a Monoisotopic mass is indicated.
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and 24 h. Chromatograms from the purification of the folded
peptides are shown in Fig. 2.
The late eluting peaks were purified and analyzed by NMR
spectroscopy to confirm that the native fold was present. A
comparison of the H chemical shifts of the grafted peptides
with the native peptide is shown in Fig. 3. The comparison
indicates that the overall structures of the peptides are sim-
ilar. The only H chemical shift differences larger than 0.2
ppm were found for Val29, which is the C-terminal neighbor
to the grafted sequence, Cys1, which is bound to Val29, and
Cys15, which forms a disulfide with Cys1. The peptides
kB1(HFRW;24–27) and kB1(HfRW;24–27) had additional
peaks in the NMR spectra (data not shown) deriving from cis/
trans-isomerization at the Trp27/Pro28 peptide bond. The
major conformation, judging from the intensity of the peaks,
was the cis-Pro conformation. The two conformers of
kB1(HfRW;24–27) were distinguished by a strong NOE cross-
peak between the H-H protons of Trp27 and Pro28 (4.24
ppm; 3.33 ppm) in the major conformation and a weaker NOE
cross-peak between H-H protons (5.01 ppm; 3.91 ppm) in
the minor conformation.
Melanocortin Assays—The binding affinities of the four syn-
thesized melanocortin analogues of kalata B1 to MCR1 and
MCR3–5were determined by competition binding assays using
radiolabeled NDP--MSH. Kalata B1 and -MSH were also
evaluated as controls. The results are given in Table 2, and
results from binding studies of kalata B1, kB1(GHFRWG;23–
28) and -MSH at the MC4R are shown in Fig. 4. Peptide
kB1(GHFRWG;23–28) had a Ki of 29 nM at the MC4R and was
107 or 314 times selective for the MC4R over the MC1R or
MC5R, respectively. The peptide did not bind to the MC3R.
The Ki value of -MSH at the MC4R receptor was 39 nM. Pep-
tide kB1(GHFRWG;23–28) was also tested in a functional assay
to evaluate the potency at the MC4R and was found to have an
EC50 of 580 nM, whereas -MSH had an EC50 of 3.7 nM (Table 2).
Three-dimensional Structure of kB1(GHFRWG;23–28)—Given
thepotency and selectivity observed for kB1(GHFRWG;23–28),
its three-dimensional structure was determined to provide
insight into structure-activity relationships. Structures were
determined using torsion angle dynamics in the program
CYANA, and the 20 structures with the lowest target function
were chosen to represent the global fold. Energetic and geomet-
ric statistics are given in Table 3. Analysis of the structures with
PROMOTIF (53) revealed that the major element of secondary
structure is a -hairpin involving residues 16–18 and 21–23. A
third strand comprising residues 3–4 is associated with the
hairpin to form a triple-stranded -sheet as shown in Fig. 5. In
addition, residues 5–8 form a type I-turn, and residues 10–12
and 12–14 form inverse -turns. Comparison of the structure
of kB1(GHFRWG;23–28) with the native kalata B1 framework
indicates that the overall fold is maintained. The cyclic cystine
knot motif and -hairpin are the defining structural features of
the cyclotides, and both are present in kB1(GHFRWG;23–28),
despite the sequence changes in loop 6. The introduction of
non-native sequences into the CCK scaffold can sometimes
lead to disordered loops (45, 48). However, for kB1(GHFRWG;
23–28) the grafted loop 6 is as well defined as the other loops,
with order parameters 0.93 for the  and  angles over the
whole molecule.
The grafted sequence has several large hydrophobic residues,
including His, Phe, and Trp as shown in Fig. 5b, and it was of
interest to determine how their presence might influence the
nature of the molecular surface. Analysis of the surface of
kB1(GHFRWG;23–28) shows that a group of surface-ex-
posed hydrophobic residues is punctated by polar or charged
residues. In addition, the arginine in loop 6 is highly solvent-ex-
posed.A similar distributionof surface residues is evident inkalata
B1, with the exception of loop 6, as illustrated in Fig. 6.
Proteolytic Stability—To investigate the stability of the pep-
tides, kalata B1, kB1(GHFRWG;23–28) and -MSHwere incu-
bated with chymotrypsin. As shown in Fig. 7, more than 95% of
kalata B1 remained intact for 5 h. Peptide kB1(GHFRWG;23–
28) was slightly less stable, but around 80% was intact after 5 h.
After 24 h, the amounts of intact peptide had not changed fur-
ther, but this is probably due to auto-cleavage and deactivation
of chymotrypsin by this time. Compared with kalata B1,
FIGURE 2. Chromatograms from the preparative HPLC purifications of
the grafted peptides. The peaks corresponding to the correctly folded pep-
tides are marked with an asterisk.
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kB1(GHFRWG;23–28) has two additional potential chymo-
trypsin cleavage sites in the grafted sequence, so the observed
resistance to proteolysis is a significant finding. Finally, -MSH
completely degraded within 10 min.
DISCUSSION
In this study we used the kalata B1 cyclotide scaffold to
design a novel agonist for the MC4R. This analogue
(kB1(GHFRWG;23–28)) also showed selectivity over other
FIGURE 3. H chemical shifts of the four synthesized peptides and kalata B1. The numbers corresponding to cysteine residues are highlighted in
boldface.
TABLE 2
Binding affinity of grafted cyclotides for melanocortin receptors 1 and 3–5 and functional activity at MCR4 of the most potent binder
NAmeans no activity (i.e. Ki10,000 nM). Data represent an average pKi of three replicates S.E.Ki value (in parentheses) is calculated from the average pKi value. Potency
at the MC4R was determined only for kB1(GHFRWG;23–28).
Peptide hMC1R, pKi hMC3R, pKi hMC4R, pKi hMC4R, cAMP pEC50 hMC5R, pKi
Ki/nM Ki/nM Ki/nM EC50/nM Ki/nM
Kalata B1 NA NA NA NA
kB1(GHFRWG;23–28) 5.50 0.09 NA 7.53 0.28 6.24 0.08 5.04 0.14
(3,100) (29) (580) (9,100)
kB1(GHfRWG;23–28) 6.37 0.06 5.11 0.03 6.59 0.15 5.30 0.04
(420) (7,700) (250) (5,000)
kB1(HFRW;24–27) NA NA NA NA
kB1(HfRW;24–27) NA Na NA NA
-MSH 9.16 0.05 7.51 0.04 7.41 0.26 8.44 0.26 6.75 0.16
(0.69) (31) (39) (3.7) (180)
FIGURE 4. MC4R binding assays for kB1(GHFRWG;23–28), kalata B1 and
-MSH. Each assay was performed in duplicate. Cell membranes expressing
the MC4R were incubated with 125I-NDP--MSH and the synthesized pep-
tides. The amount of radioactivity frombound 125I-NDP--MSHwas counted,
and Ki valueswere calculated. Data points are average values from the assays,
and S.E. values are indicated with error bars.
TABLE 3
NMRand refinement statistics for the structure of kB1(GHFRWG;23–28)
NMR distance and dihedral constraints
Distance constraints
Total NOE 291
Short range (i j1) 202
Medium range (1(i j5) 42




CYANA target function 1.02 0.07
Violations (mean S.D.)
Distance constraints, r.m.s.d. 0.01 0.002 Å
Dihedral angle constraints, r.m.s.d. 1.45 0.12°
Maximum distance constraint violation 0.26 Å
Max. dihedral angle violation 1.01°
Average pairwise r.m.s.d.a
Backbone 0.41 0.11 Å
Heavy 0.84 0.18 Å
Ramachandran statistics
Residues is most favored regions 49.5%
Residues in additionally allowed regions 50.5%
a Pairwise root mean square deviation (r.m.s.d.) was calculated from the 20 struc-
tures with the lowest target function.
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MCRs tested, highlighting the potential of the CCK scaffold for
targeting specific interactions implicated in the regulation of
appetite and energy homeostasis and providing a possible
lead molecule for the treatment of obesity. Interestingly,
kB1(GHFRWG;23–28) showed higher affinity for the MC4R
compared with the native agonist -MSH, but it was not as
potent functionally. It appears likely that kB1(GHFRWG;23–
28) has stronger binding to the active site than -MSH, but due
to the placement of the pharmacophore within the kalata B1
scaffold and possible steric clashes with the receptor, it is not
able to induce a similar conformational change in the receptor,
which is required for full activation of the cAMP cascade. Nev-
ertheless, significant (sub-micromolar) activation of the cAMP
response was observed. This successful example of grafting a
function into a cyclotide adds to a growing body of evidence
that the CCK framework can accommodate a diverse range of
bioactivities.
Four analogues of kalata B1 were synthesized using Boc
chemistry and generally folded well using the oxidation condi-
tions previously established for native kalata B1 (Fig. 2). All of
the analogues retained the native fold based on analysis with
NMR spectroscopy. Even though six of the seven residues in
loop 6 were replaced, the CCK holds the remaining loops in
place and allows these changes in loop 6. The grafted sequence
is significantly more hydrophobic than sequences previously
grafted into this framework, and this study expands the known
sequence diversity accommodated by the cyclotide scaffold
(44–46, 48), and in particular highlights the tolerance of loop 6
to changes. This tolerance is further demonstrated by observa-
tions that loop 6 can be truncated and opened to produce acy-
clic cystine knot derivatives that maintain the same global fold
as kalata B1 (57). In essence, the exposed loops of the CCK
framework can be regarded as “plug and play” cassettes that can
be substituted to introduce a desired biological activity.
Interestingly, kB1(GHfRWG;23–28), the D-Phe25 analogue
of kB1(GHFRWG;23–28) bound with lower affinity to the
MCRs than the all-L graft. This was surprising because D-Phe
analogues of short linear peptides are known to have higher
affinity for the MCRs compared with the L-Phe analogues (20).
The locked conformation of the pharmacophore in loop 6 of
kalata B1 could change the presentation to the active site of the
receptors and consequently be an explanation for this observa-
tion. There is clearly potential for further optimization of the
bioactive epitope, and these studies are planned in our
laboratory.
FIGURE 5. a, overlay of the 20 minimum energy structures of kB1(GHFRWG;
23–28). b, overlay highlighting the side chains of loop 6 shown in stick format.
c, ribbonmodel of theNMR-derived structure of kB1(GHFRWG;23–28). Protein
Data Bank code 2lur. d, ribbon model of kalata B1. Protein Data Bank code
1nb1.
FIGURE 6. Surface representation of kB1(GHFRWG;23–28) (left) and
kalataB1 (right). Theonlymajor differences are observed in thegrafted loop
6, i.e. residues 23–28. Hydrophobic residues are highlighted in green, posi-
tively charged inblue, negatively charged in red, cysteines in yellow, andpolar
in cyan. The top views have similar orientation as the ribbonmodels in Fig. 5.
The residues F25, R26, andW27 in kB1(GHFRWG;23–28) are part of the mela-
nocortin pharmacophore grafted into loop 6 of kalata B1.
FIGURE 7. Enzymatic stability of kalata B1, kB1(GHFRWG;23–28), and
-MSH toward chymotrypsin cleavage. The peptides were incubated with
chymotrypsin for 5 h at 37 °C. The enzyme to peptide ratio was 1:5 w/w (1:10
w/w for -MSH to have equal molar ratios). The inset shows the degradation
of -MSH the first 10 min of incubation.
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NMR spectra for kB1(HFRW;24–27) and kB1(HfRW;24–
27) revealed that two conformations were present. This confor-
mational heterogeneity appears to be related to cis/trans-
isomerization aroundPro28. Themajor conformation, based on
inter-residue cross-peaks was the cis-conformation. This was
confirmed by a strong H-H cross-peak between Trp27 and
Pro28. The cis-Pro conformation is consistent with what has
previously been described for the Trp19–Pro20 bond in kalata
B1 (35, 58). The strong H-H cross-peak between Trp19 and
Pro20was observed in all peptides, whereas aH-H cross-peak
was observed for the Thr12–Pro13 bond. The cis-Pro20 bond
causes a conceptual twist in the backbone, which defines the
Mo¨bius family of cyclotides (35). The additional twist caused by
the cis-Pro28 bond changes the topology of kB1(HFRW;24–27)
and kB1(HfRW;24–27). This could be part of the reason why
they did not bind to theMCRs, because a twist in the backbone
around the pharmacophore changes the presentation of the
side chains at the active site of the receptors. Besides the con-
formational change, it is also possible that the side chains of
Thr23 and Pro28 in kB1(HFRW;24–27) and kB1(HfRW;24–27)
affect the binding of the pharmacophore to the active site of
the MCRs negatively compared with Gly23 and Gly28 in
kB1(GHFRWG;23–28) and kB1(GHfRWG;23–28), which due
to their lack of side chain would interfere less with the active
site.
The intrinsic resistance of-MSH to proteolytic degradation
is very low but can be somewhat increased by engineering a
single disulfide in the sequence (59). Kalata B1 has been dem-
onstrated to have significantly increased stability toward enzy-
matic degradation compared with noncystine-knotted ana-
logues, linear cystine-knotted peptides, and noncyclic peptides
(40). It was of interest to determine whether the target-grafting
epitope would have enhanced resistance to proteolysis when
incorporated into the cyclotide framework. Chymotrypsin
cleavage assays for kB1(GHFRWG;23–28), kalata B1, and
-MSH confirmed this expectation. Whereas -MSH was
completely degraded within 10 min under the conditions
studied, kalata B1 was 95% intact after 5 h and remained
stable even after 24 h, probably due to auto-cleavage of chy-
motrypsin. KB1(GHFRWG;23–28) was only slightly less sta-
ble than kalata B1, being 80% intact after 5 h. This marginal
loss of stability is surprising on the one hand because the
grafted sequence in loop 6 contains two potential chymo-
trypsin cleavage sites and hence the sequence is intrinsically
susceptible to proteolysis. On the other hand, the results
provide clear confirmation of the ability of the cyclotide
framework to stabilize even a “susceptible” epitope. The
observation that kB1(GHFRWG;23–28) was more than 80%
intact after extended incubation with chymotrypsin con-
firms the high stability toward enzymatic degradation of
both kalata B1 and grafted analogues thereof.
Cyclotides and other cystine knot micro-proteins have been
suggested to have the potential for oral delivery, partly because
of their high stability (60, 61). This potential was recently dem-
onstrated in the development of an analogue of kalata B1 that is
orally active in a mouse model of inflammatory pain (46), sug-
gesting that similar exciting results for the oral route of drug
delivery might be achieved with other examples of kalata B1
grafting. The analogues of kalata B1 reported here represent a
new group of selective melanocortin agonists. Because of their
cyclotide framework, they are more stable than previously
reported linear and mono-cyclic melanocortin analogues, and
with further optimization this group of peptides could provide
new peptide-based leads with the potential to treat obesity.
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